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Abstract: Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been con
even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to  
APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths 
can  to  a  large  extent  be  avoided  if  specific  measure
referral  to  a  specialized  center,  immediate  onset  of  ATRA  and  chemotherapy,  treatment  of 
coagulopathy  with  adequate platelet transfusional  support, and  prevention and  management of 
differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement 
with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, 
especially  with  ATRA  and  low  dose  chemotherapy,  and  possibly,  although  this  is  debated, 
intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, 
outcomes of patients with high risk APL have considerably improved, and have become in many 
studies almost similar to those of standard risk APL patients.
Introduction: Acute promyelocytic leukemia (APL) is 
a  distinct  type  of  acute  myeloid  leukemia  (AML) 
characterized by specific morphology (M3 in the FAB 
classification), frequent association of a
the t(15:17) translocation resulting in the fusion protein 
PML-RARα. The APL has a  specific sensitivity to the 
differentiating  properties  of  all-trans  retinoic  acid 
(ATRA) and the proapoptotic effect of arsenic trioxide 
(ATO), which have, in combination with anthracyline
based  chemotherapy,  considerably  improved  its 
prognosis in the last 20 years.
1-6
WBC counts are generally low in APL, with only 
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Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been con
trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to  
APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths 
can  to  a  large  extent  be  avoided  if  specific  measures  are  rapidly  instigated,  including  prompt 
referral  to  a  specialized  center,  immediate  onset  of  ATRA  and  chemotherapy,  treatment  of 
coagulopathy  with  adequate platelet transfusional  support, and  prevention and  management of 
gies to reduce relapse rate include chemotherapy reinforcement 
with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, 
especially  with  ATRA  and  low  dose  chemotherapy,  and  possibly,  although  this  is  debated, 
l prophylaxis to prevent central nervous system relapse. By applying those measures, 
outcomes of patients with high risk APL have considerably improved, and have become in many 
studies almost similar to those of standard risk APL patients.
Acute promyelocytic leukemia (APL) is 
a  distinct  type  of  acute  myeloid  leukemia  (AML) 
characterized by specific morphology (M3 in the FAB 
association of a coagulopathy, 
the t(15:17) translocation resulting in the fusion protein 
RARα. The APL has a  specific sensitivity to the 
trans  retinoic  acid 
(ATRA) and the proapoptotic effect of arsenic trioxide 
), which have, in combination with anthracyline-
based  chemotherapy,  considerably  improved  its 
WBC counts are generally low in APL, with only 
20-25% and <5% of patients having WBC higher than 
10 G/L and 50 G/L, respectivel
have always been associated with poorer prognosis in 
APL,  even  since  the  advent  of  ATRA,  but  recent 
results suggest that the outcome of those patients may 
have become almost similar to that of APL with lower 
WBC counts, with the opti
tools, including early massive transfusional support.
Characteristics  and  prognosis  of  APL  with 
increased  WBC  counts: 22.6%,  6.1%  and  1.4%  of 
902 patients, included in combined an
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Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, 
trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to  
APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths 
s  are  rapidly  instigated,  including  prompt 
referral  to  a  specialized  center,  immediate  onset  of  ATRA  and  chemotherapy,  treatment  of 
coagulopathy  with  adequate platelet transfusional  support, and  prevention and  management of 
gies to reduce relapse rate include chemotherapy reinforcement 
with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, 
especially  with  ATRA  and  low  dose  chemotherapy,  and  possibly,  although  this  is  debated, 
l prophylaxis to prevent central nervous system relapse. By applying those measures, 
outcomes of patients with high risk APL have considerably improved, and have become in many 
25% and <5% of patients having WBC higher than 
10 G/L and 50 G/L, respectively.
7-11 High WBC counts 
have always been associated with poorer prognosis in 
APL,  even  since  the  advent  of  ATRA,  but  recent 
results suggest that the outcome of those patients may 
have become almost similar to that of APL with lower 
WBC counts, with the optimal use of all therapeutic 
tools, including early massive transfusional support.
Characteristics  and  prognosis  of  APL  with 
22.6%,  6.1%  and  1.4%  of 
902 patients, included in combined analysis of APL 93 Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
and APL 2000 trials of the European APL group,  had 
WBC  10-50  G/L,  50-100  G/L  and  >100  G/L, 
respectively.
12 The 10 G/L and 50 G/L thresholds for 
WBC are used hereafter to define APL with high and 
very high WBC. APL with high WBC is more frequent 
in  children  and  is  often  associated  with  the 
microgranular  variant  (M3v),  with  the  short  PML-
RARα isoform (bcr3), with the FLT3 mutation and the 
CD56  expression  which    are  all  adverse  prognostic 
factors in APL, although not independent from WBC 
counts.
13-18 APL  with  increased  WBC  is  frequently 
associated  with  severe  coagulopathy  and,  sometimes 
with organomegaly. The fibrinogen level is indeed <1.5 
g/L in at least half the patients with increased WBC 
and  is  often  accompanied  by  severe  hemorrhagic 
manifestations,  intracranial  hemorrhage  either  at 
presentation  or  during  the  first  days  of  remission 
induction obviously being the most severe. Before the 
ATRA era, i.e. in patients treated with anthracycline-
based  chemotherapy,  early  mortality  in  patients  with 
increased WBC averaged 50-70%, but even in the early 
ATRA  era,  most  studies  found  an  increased  early 
mortality  (10-20%)  in  patients  with  high  WBC 
counts.
7,19-21 They  also  found,  by  comparison  with 
patients with WBC<10 G/L, an increased incidence of 
relapse  (30%),  including  of  central  nervous  system 
(CNS) relapse (Tables 1 and 2).
8,9,22-28 This increased 
relapse risk led to the design of Sanz score for APL 
relapse, discriminating between low and intermediate 
risk (hereafter referred to as standard risk) patients with 
WBC <10 G/L and platelet counts more and less than 
40 G/L, respectively, and high risk patients with WBC 
counts  greater  than  10  G/L.
29 In that  study,  with  an 
ATRA  and  anthracycline-based  regimen,  3-year 
relapse-free survival was 100%, 90% and 75% for low, 
intermediate and high risk patients, respectively. Thus, 
preventing relapse is particularly relevant for high risk 
patients.  In  addition,  considering  that  event-free 
survival (EFS) and OS are probably better after salvage 
treatment  delivered  at  the  molecular  relapse  stage 
(rather  than  at  full blown  hematologic  relapse), 
monitoring of PML-RARα  after  CR achievement    is 
particularly important  for high risk patients.
30-32
Management of  APL with Increased WBC Counts
-1)  Preventing  early  mortality: Hyperleukocytic 
APL is, even more than standard risk APL, a medical 
emergency.  An  undetermined  percentage  of  patients 
with  high  and  very  high  WBC  die  before  treatment 
onset without being registered in clinical trials.
33 Early 
mortality rates as high as 42% have been reported in 
APL patients with high WBC, many of those deaths 
occurring  before  patients  could  reach  a  specialized 
hospital facility, let alone be included in a clinical trial, 
while in a report from Surveillance, Epidemiology, and 
End Results (SEER) an overall early mortality rate of 
17%  was  reported  in  APL,  which  was  presumably 
more in patients with high WBC counts.
34,35 The risk of 
early mortality being particularly high during the first 
days of treatment, specific measures must be urgently 
implemented  to  prevent  those  early  fatalities. 
Resistance to  ATRA-based  induction regimens  being 
very rare (<1/500 cases), induction remission failures 
actually reflect early mortality. Published trials of the 
modern era  reporting on early mortality of high risk 
patients are listed in Table 1 although, as said above, 
they  may  sometimes  underestimate  the  reality,  some 
patients possibly dying before they can enter a clinical 
trial.
Bleeding,  particularly  in  the  CNS,  is  the  leading 
cause  of  early  and  very  early  (<48  h)  mortality. 
Presence of coagulopathy, high WBC and higher than 
normal  creatinine  levels  have  been  identified  as 
predictive  factors  of  fatal  hemorrhage.
36,37
Coagulopathy should be treated intensively with fresh 
frozen  plasma  and  high  dose  prophylactic  platelet 
transfusions  in  order  to  maintain  platelet counts ≥50 
G/L  until  normalization  of  bleeding  parameters.  In 
accordance  with  published  guidelines,  invasive 
procedures  including  placement  of  central  venous 
catheters and leukapheresis are contra-indicated during 
induction  remission.
34 Any  delay  in  diagnosis  and 
treatment  initiation  in  hyperleukocytic  APL  is 
unequivocally  associated  with  a  higher  risk  of  early 
hemorrhagic death.
38 ATRA has a rapid impact on both 
fibrinolytic  and  procoagulant  aspects  of  the 
coagulopathy, and should be initiated as soon as the 
diagnosis  of  APL  is  clinically  or  morphologically 
suspected. However, at least in hyperleukocytic forms, 
chemotherapy should be started concomitantly, in order 
to avoid a life threatening differentiation syndrome (see 
below).  This  concomitant  use  of  ATRA  and 
chemotherapy had led to reduction of early mortality in 
patients with very high WBC (>50 G/L), from at least 
50% before the ATRA era to 18% in the APL93 trial.
8
Differentiation  syndrome  (DS)  with  ATRA,  with 
manifestations  of  unexplained  respiratory  failure, 
pulmonary  infiltrates,  fever,  weight  gain, 
pleuropericardial  effusions,  hypotension  and  renal 
failure, usually occurring concomitantly with a rise in 
WBC count, is another major cause of early mortality 
in  high  risk  patients.
39,40,41 Severe  DS,  requiring 
mechanical ventilation or complicated with pericarditis 
or  life  threatening  hemorrhage,  is  more  frequent  in 
patients  with  high  presenting  WBC  counts.  Early 
recognition and systematic prevention of DS with high-
dose  dexamethasone  from  the  first  day  of  treatment 
certainly contributed to reduce the number of fatal DS 
from 5.7% to 3.9%, among high risk patients included 
in two consecutive trials of the European APL group Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Early mortality of high risk (HR) patients in modern era clinical trials according to the type of induction treatment.
Study Years of study Nb of HR pts Early death rate (%)
ATRA/anthracycline, with standard dose AraC
Fenaux et al APL 93
8 1993-1998 139 12.2%
Adès et al APL 2000
9 2000-2006 133 7.4%
Adès et al APL 2006
42 2006-… 45 0
Powell et al C9710
23 1999-2005 113 20%
ATRA/anthracycline with  high-dose AraC
Lengfelder et al AMLCG
24 1994-2005 37 16.2%
ATRA/anthracycline without  AraC
Sanz et al LPA99
26 1996-2005 140 19%
Sanz et al LPA2005
27 2005-2009 118 17%
ATO monotherapy
Ghavamzadeh et al
49 1999-2010 37 42%
ATO+/-ATRA+chemotherapy
Hu et al (ATRA/ATO/chemotherapy)
50 2001-2005 19 5%
Ravandi et al (ATRA/ATO/gemtuzumab 
ozogamycin or idarubucin)
47 2002-2008 47 19%
(APL 93 and APL 2000).
12
Overall,  improved  DS  management  and 
transfusional  support  were  likely  the  key  factors  of 
reduction of early mortality between our APL 93 and  
2000 trials, from 10.4% to 7% in patients with high 
WBC counts, and 18% to 9% in patients with very high 
WBC counts. In APL 2000 trial, the early death rate 
was  not  dependent  from  WBC  count.
12Moreover,  in 
our ongoing APL 2006 trial, using the same induction 
regimen  of  ATRA  and  anthracycline  based 
chemotherapy  (with  substitution  of  idarubicin  for 
daunorubicin),  none  of  the  45  high  risk  patients  
included had early death.
42
-2) Preventing relapse: Presenting WBC >10 G/L 
remains  the  strongest  prognostic  factor  for  relapse, 
including  for  extramedullary  relapse,  especially  in 
CNS.  Several  strategies  can  reduce  the  incidence  of 
relapse  in  those  patients,  and    attenuate  the  adverse 
prognostic  character  of  hyperleukocytic  APL,  which 
was no more significant in our recent experience.
a)  Cytarabine  during  induction  and 
consolidation  treatment:  While  anthracycline-based 
regimens  without  AraC  have  been  preferred  to  limit 
toxicity  in  low  and  intermediate  risk  APL  patients, 
several  lines  of  evidence  strongly  support  that 
cytarabine  added  to  anthracycline  during  remission 
induction and consolidation treatment may contribute 
to reduce relapses in high risk patients.
Indeed,  very  few  relapses    occurred  in  our  APL 
2000  trial  and  in  a  German  study  using  high  dose 
cytarabine,  added  to  anthracyclines,  during 
consolidation,    (Table  2).
9,24,43 In  addition,  a  joint 
analysis of the European group trial APL 2000 and the 
Spanish  PETHEMA  trial  LPA  99,  which  used  no 
cytarabine during induction and consolidation, showed 
a significant advantage, in terms of EFS, CIR and OS 
in  high  risk  patients  included  in  APL  2000  trial.
44
Finally,  risk-stratification  in  the  subsequent 
PETHEMA-HOVON  LPA  2005  trial,  based  on 
reinforcement of consolidation with cytarabine in high 
risk patients, reduced relapse rate by comparison with 
LPA99 trial.
26
The dose of cytarabine could also be of importance. 
Increasing the total cytarabine dose from 8 to 20 g/m2 
during the second consolidation cycle indeed possibly 
contributed to the lower incidence of relapse of patients 
with high and very high  WBC count included in APL 
2000, compared with APL 93 trial.
12 Moreover, long 
term analysis of our APL 2000 trial found that outcome 
of high risk patients was better than that of standard 
risk patients treated without cytarabine.
43
b)  Maintenance treatment:  In our  experience, 
maintenance  treatment  with  continuous  low  dose 
6MP+MTX  and  intermittent  ATRA  is  particularly 
useful in high risk patients. Its impact on the long-term 
outcome  was  clearly  demonstrated  in  the  very  long 
term analysis of the  randomized APL 93 trial where 
10-y  CIR  was  68.4%,  53.1%,  32.8%  and  20.6%  in 
patients  with  WBC  >5  G/L  who  had  received  no 
maintenance,  maintenance  with  only  ATRA,  only 
chemotherapy  (6MP  and  MTX)  and  combinedMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 2. Published clinical trials reporting  long-term outcome in high risk (HR) patients according to the type of consolidation.
Study Years of study Nb of HR pts Relapse OS
AraC-containing consolidation
Adès et al APL 9322
9 1993-1998 139
WBC>5 G/L: 10y-CIR 
37.8%
WBC>5 G/L: 10y-OS 
63.1%
Adès et al APL 2000
9 2000-2006 133 5y-CIR 7.5% 5y-OS 89.8%
Lengfelder et al AMLCG
24 1994-2005 37 10y-CIR 11.4% 10y-OS 73%
Grimwade et al AML15
31 2002-2009 55 3y-CIR 10% (+/- AraC) -
Risk-stratification consolidation
AraC added to ATRA/anthracycline for HR patients
Sanz et al LPA99
26 1996-2005 140 4y-CIR 27% 4y-OS 68%
Sanz et al LPA2005
27 2005-2009 118 4y-CIR 14% 4y-OS 79%
ATRA added to AraC/anthracycline for HR patients
Lo-Cocco et al AIDA-0493
28 1993-2000 176 6y-CIR 49.7% 6y-OS 61.3%
Lo-Cocco et al AIDA-2000
29 2000-2006 129 6y-CIR 9.3% 6y-OS 83.4%
ATO studies
ATO monotherapy
Mathews et al
48 1998-2004 17 5y-EFS 60% -
Ghavamzadeh et al
49 1999-2010 38
All risks: 5y-DFS 66.7%
No difference between HR 
pts and others
All risks: 5y-OS 64.4%
No difference between HR 
pts and others
ATO+chemotherapy
Hu et al (ATRA/ATO/chemotherapy)
50 2001-2005 19 5y-EFS 83.2% 5y-OS 89.2%
Ravandi et al (ATRA/ATO/gemtuzumab 
ozogamycin or Idarubicin)
47 2002-2008 47 3y-EFS 60% 3y-OS 60%
Powell et al ATO+
23 1999-2005 55 5y-EFS 60% 5y-OS 80%
Powell et al ATO-
23 1999-2005 58 5y-EFS 35% 5y-OS 40%
maintenance  with  ATRA+chemotherapy,  respectively 
(P<0.001).  The  difference  was  less  important  for 
patients with WBC <5 G/L, suggesting that combined 
maintenance  treatment  mostly  benefited  high  risk 
patients.
22 Moreover, a combined analysis of APL 93 
trial (where not all patients received maintenance) and 
APL  2000  trial,  where  combined  maintenance 
treatment was systematic, showed that, in patients with 
WBC count >10 G/L, receiving combined maintenance 
treatment  was  the  strongest  prognostic  factor 
associated with reduction of CIR and increase in OS.
12
We  also  found  discontinuation  of  this  maintenance 
treatment after less than one year to be associated with 
an  increased  risk  of  relapse.  Two-year  combined 
maintenance  with  intermittent  ATRA  and  low  dose 
chemotherapy  thus  appears  to further  improve     the 
outcome  of  hyperleukocytic  APL.  This  treatment  is 
associated  with  no  excessive  toxicity,  provided  co 
mplete  blood  count  is  regularly  monitored  to  adjust 
doses and avoid excessive cytopenias.
c) Arsenic trioxide: Arsenic trioxide is the most 
potent  single  agent  in  APL,  capable  of    inducing 
complete responses, including molecular ones, and it is 
particularly successful in the setting of molecular and 
hematologic  relapse.
32 A  US  intergroup  trial  clearly 
demonstrated the benefit of adding two cycles of single 
agent  ATO  to  a  classical  first  line  ATRA  and 
chemotherapy based regimen, particularly in high risk 
patients.
24 In addition, 5-year EFS of high risk patients 
who received ATO was not significantly different from 
that  of  standard  risk  patients,  indicating  that  ATO 
consolidation  may  overcome  the  negative  prognosis 
conferred  by  high  risk  disease.  Other  studies  using 
ATO  during  consolidation  also  generated  promising 
results (Table 2).
45-47 In contrast, induction with ATO 
monotherapy  is  considered  more  experimental,  in 
particular due to the fact that high risk patients have a 
major  risk of  developing  severe  DS,  unless Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
chemotherapy  is  administered  concomitantly.
48,49
Nevertheless, once CR is achieved, durable responses 
have been reported with this approach.
Thus, although ATO may become frequently used 
in the front-line induction therapy of APL, published 
results caution against using it without chemotherapy 
in  high  risk patients.  In its  current  randomized  APL 
2006 trial, the European APL group is investigating the 
impact  of  ATO  versus  that  of  AraC  during 
consolidation in high risk patients.
42
d)  Prevention  of  CNS  relapse:  High  WBC 
count  is  also  a  major  risk  factor  for  extramedullary 
relapse,  in  particular  CNS  relapse,  although  its 
incidence is small (cumulative incidence of 5% among 
high  risk  patients).
51,52 Given  the  published  poor 
prognosis  of  extramedullary  relapse,
51 CNS 
prophylaxis  with  intrathecal  chemotherapy  may  be 
considered systematically in high risk patients. Agents 
that  cross  the  blood-brain  barrier  such  as  high  dose 
cytarabine or arsenic trioxide (ATO) may also reduce 
that risk. In APL 93 trial, using high dose cytarabine, 3 
(0.9%) patients in CR had CNS relapse as compared 
with 15 (2.5%) and 9 (2.1%) patients in AIDA 0493 
and AIDA 2000 trials, respectively, where the dose of 
AraC  was  conventional.
22,27,28 Moreover,  systematic
CNS prophylaxis with 5 triple intrathecal injections, in 
addition to higher dose cytarabine, in patients with high 
WBC count in APL 2000 trial was associated with the 
absence of CNS or other extramedullary relapse. The 
German AMLCG study using higher dose cytarabine 
also reported no CNS or other extramedullary relapse 
in standard and high risk patients.
24 Despite penetration 
in cerebrospinal fluid, prolonged use of ATO did not 
seem  efficacious  in  preventing  CNS  relapse  in  the 
absence  of  intrathecal  chemotherapy  in  one  study, 
where all 4 relapses (among 80 patients)  involved the 
CNS.
50
However, other authors consider the number of high 
risk patients to treat prophylactically too high given the 
overall low incidence of CNS relapse.
52 Also of note is 
that, since the advent of ATO to treat relapse, outcome 
of  patients  with  CNS  relapse  has  been  better  in  our 
experience  than  with  previously  used  salvage 
regimens.
53
-3)  APL  with  high  WBC  counts  in  specific  age 
groups:
a)  Children:  The  frequency  of  high  WBC 
counts in  children  is  relatively  high  and  even  more 
(50%)  in  children  aged  <12  years.
13-16 In  our 
experience, children aged <4 years have a higher risk 
of relapse even with prolonged maintenance treatment 
and high dose AraC.
16 For older children, EFS did not 
differ  from  that  of  adults after  adjustment  for  WBC 
counts, and OS was often better due to better results of 
salvage  treatment.
14 High  risk  pediatric  patients 
included in Italian trials had a 10-year EFS of 59%, 
significantly worse than in standard risk patients, while 
the Spanish group reported an overall 5-year CIR of 
31% in children with high WBC counts. By contrast, 
similar outcomes were reported in high and standard 
risk  patients  in  a  Japanese  study  using  cytarabine, 
added to ATRA and anthracyclines.
54
ATO, in combination to ATRA and chemotherapy, 
may offer an interesting perspective for disease control 
in pediatric patients with high WBC counts, especially 
in those aged <4 years, associated in our experience to 
a higher relapse risk. No chronic arsenic toxicity was 
observed  in  a  Chinese  report  on  childhood  APL, 
despite protracted intermittent administration of ATO 
used as a single agent.
55
b)  Elderly  patients:  Approximately  20%  of 
APL patients are aged over 60 years, with a proportion 
of  cases  with  WBC  >10  G/L  slightly  lower  than  in 
younger adults (20% vs. 23% high risk patients among 
those aged ≥60 years vs. 19-59 years, respectively, in 
the  PETHEMA  studies).
56-58 Increased  incidence  of 
early deaths and deaths in CR in elderly APL patients 
in  general  renders  particularly  challenging  the 
management  of  those  patients,  especially  those  with 
high risk features. Indeed, in both the GIMEMA and 
PETHEMA studies, one third of elderly patients died 
during induction remission.
56,57 Early deaths were due 
to  hemorrhage and  DS  but  also  to  cardiac 
complications.
56 Relapse  rate  of  high  risk  elderly 
patients  is  similar  to  that  of  high  risk  younger 
patients.
58 Age above 50 years, in spite of absence of 
CIR  difference  across  age groups,  was,  however,  an 
adverse prognostic factor for EFS and OS in high and 
very  high  risk  patients,  in  the  combined  analysis  of 
APL  93  and  APL  2000  trials.
12 Rather  than  age-
adjusted chemotherapy dosage, incorporation of ATO 
in  current  regimens  could  counteract  those  adverse 
features with better disease control.
Conclusion: Improvement  in  outcomes  of  APL 
patients with high WBC counts was made possible by 
combining specific measures to prevent early mortality 
and  relapse.  Those  results  indicate  that,  with  risk-
tailored management, outcome of APL patients could 
become  independent  of  WBC  counts  in  the  Acute 
promyelocytic  leukemia.  More  investigation  and 
efforts are still needed to reduce very early mortality 
not reflected by clinical trials results.
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